Skip to main content
. 2022 Jun 11;29(6):4224–4234. doi: 10.3390/curroncol29060337

Table 4.

Univariate analysis for tpCR by trastuzumab product.

Total (n = 136) TRZ (n = 77) MYL-1401O (n = 59) p-Value
tpCR—Yes 52 (38.2%) 31 (40.3%) 21 (35.6%) 0.598
tpCR—No 84 (61.8%) 46 (59.7%) 38 (64.4%)

TRZ (reference trastuzumab), tpCR (total pathological complete response).